Skip to content

Depression: all studies

Page 349 of 1,034: studies 3,481 to 3,490 of 10,336, newest first. Back to the depression overview

Research

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction July 24, 2025 Amandine Luquiens, Dahbia Belahda, Carine Graux et al. 22 citations

Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted psychotherapy for patients with comorbid...

DOI: 10.1111/add.70152 (opens in new tab) Alcohol use disorder Dual disorders Feasibility Psychedelics +14

Differential effects of mindfulness and grit on positive mental health outcomes in major depressive and bipolar disorders: A moderation analysis using an ecological momentary assessment approach.

Journal of Affective Disorders July 23, 2025 Joyce Xu Hao Jin, Heidi Ka Ying Lo, Iris Wai Tung Tsui et al. 2 citations

Holistic management of persons living with Major Depressive Disorder (MDD) and Bipolar Disorder (BD) invites the need for evaluation of positive mental health (PMH; pleasure attainment and meaning-in-life), alongside conventional measures of psychopathology. The aforementioned dimensions of PMH involve aspects of mindfulness and grit. Herein, we evaluate these aspects using ecological momentary...

Radiation therapy patients' interest in psychedelic-assisted therapy: results of a survey.

Radiation oncology (London, England) July 21, 2025 Jino Park, Rufus Banks, Akul Munjal et al.

Comorbid mental health symptoms impact 30-40% of cancer patients, significantly compromising treatment adherence and increasing mortality rates. Among patients undergoing radiation therapy, which is delivered with palliative intent in nearly half of all cases and for those nearing end-of-life, these rates may be even higher. Emerging research underscores the promising potential of...

Pharmacokinetics, Safety, and Tolerability of (R)-Ketamine Hydrochloride Injection, a Novel Rapid-Acting Antidepressant, in Healthy Chinese Subjects.

Pharmaceuticals July 21, 2025 Rui Wang, Yuqian Yang, Tong Zhou et al.

Objectives: (R)-ketamine hydrochloride injection is a novel, rapid-acting antidepressant for the treatment of treatment-resistant depression. The aim of this study was to assess the pharmacokinetics, safety, and tolerability of (R)-ketamine hydrochloride injection in healthy Chinese subjects following ascending single intravenous doses ranging from 10.0 mg to 180 mg. Methods: This randomized,...

Sex-Specific Neuropsychiatric Effects of Subanesthetic Ketamine Exposure in Pregnant Mice and Their Offspring.

Cellular and molecular neurobiology July 19, 2025 Wei-Sheng Lin, Pei-Yu Wang, Sheng-Rong Yeh et al.

Depression during pregnancy is often overlooked and undertreated. Ketamine has been shown to exert prompt and sustained antidepressant effects in patients with depression, although concerns of potential neurotoxicity prohibit its use in pregnant women. Here, we aim to investigate the neurobehavioral effects of subanesthetic ketamine on pregnant mice and their offspring. We found that pregnant...

Outcomes of patients receiving interventional psychiatric procedures in a large integrated healthcare system.

Psychiatry Research July 19, 2025 Kevin J Li, Natalie E Slama, Ingrid L Chen et al. 2 citations

Interventional psychiatric procedures (IPPs) such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine intravenous treatments (KIT) are widely used for treatment resistant depression (TRD), but we lack studies of their real-world impact compared to standard outpatient medication management (MM). Longitudinal electronic health records of 22,481 patients in a...

Optimizing ketamine dosing strategies across diverse clinical applications: a comprehensive review.

Annals of Medicine and Surgery July 18, 2025 Ahmed M Kedwany, Reem Sayad, Nada S Jibril et al.

Ketamine has emerged as a versatile therapeutic agent with applications spanning anesthesia, pain management, and psychiatric disorders. This review examines ketamine's clinical utility across diverse administration routes, including intravenous, intramuscular, intranasal, and oral, emphasizing the need to individualize dosing regimens. We explore factors influencing ketamine dosing, such as...

Breath-Focused Mindfulness and Compassion Training in Parent-Child Dyads: Pilot Intervention Study.

JMIR Formative Research July 17, 2025 Satish Jaiswal, Jason Nan, Seth Dizon et al. 5 citations

Depression in children is a concerning societal issue and can be associated with poor academic performance, school dropout, and poor overall quality of life. Additionally, child depression is often associated with parallel stress and depression in parents. This scenario highlights the urgent need for the development and implementation of accessible and scalable solutions that may cobenefit...

Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.

Molecular Biology Reports July 16, 2025 Vida Mafikandi, Leila Hosseini, Fatemehsadat Seyedaghamiri et al.

Cerebrolysin (CBL), a peptide derived from pig brain, is recognized for its neuroprotective and anti-inflammatory properties. This research aimed to investigate the effects of CBL on anxiety- and depression-like behaviors, spatial memory, the tryptophan/kynurenine (TRP/KYN) pathway, and inflammation in the prefrontal cortex (PFC) of a mouse model for schizophrenia. Thirty-six male BALB/c mice...

DOI: 10.1007/s11033-025-10820-9 (opens in new tab) Full text (opens in new tab) Cognitive dysfunction Cerebrolysin: cerebrolysin Schizophrenia research: schizophrenia Model mimicking schizophrenia +7

LSD's rapid antidepressant effects are modulated by 5-HT2B receptors.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie July 16, 2025 Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al. 12 citations

Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), possess a great promise for treating affective disorders. Interestingly, LSD displays strong functional activity on 5-HT2B receptors and a modulatory role of the latter receptors in anxious and depressive-like behaviors has been reported. Using behavioral and in...